FOLFIRINOX 方案作为局部晚期胰腺癌和可切除边界胰腺癌一线化疗的荟萃分析。
Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.
机构信息
Department of Medical Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, 310006, China.
Department of Medical Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou Cancer Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
出版信息
Clin Exp Med. 2019 Feb;19(1):149-157. doi: 10.1007/s10238-018-0540-3. Epub 2018 Nov 29.
The study aimed to evaluate the effectiveness of the first-line chemotherapy FOLFIRINOX in treating pancreatic cancer. Pertinent studies were derived from the PubMed, Cochrane Library and EMBASE. The outcomes were analyzed according to resection rate and radical (R0) resection rate. Data were expressed as weighted commix proportions with 95% confidence intervals (CIs). Twenty-three studies, involving 968 patients with locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC), were examined. After treatment, 55% (95% CI 52-58%) of the patients underwent resection and 40% (95% CI 37-43%) underwent R0 resection, and the median overall survival ranged from 15.5 to 35.4 months, with a 10.0-27.1 months' median progression-free survival. The meta-analysis shows that FOLFIRINOX, as the first-line therapy, has significant down-staging effects in patients with LAPC or BRPC, with a 40% R0 resection rate and the adverse events under control.
本研究旨在评估一线化疗 FOLFIRINOX 治疗胰腺癌的疗效。相关研究来源于 PubMed、Cochrane Library 和 EMBASE。根据切除率和根治性（R0）切除率来分析结果。数据以加权混合比例表示，置信区间（CI）为 95%。共纳入 23 项研究，涉及局部晚期胰腺癌（LAPC）和边界可切除胰腺癌（BRPC）患者 968 例。治疗后，55%（95%CI 52-58%）的患者接受了切除术，40%（95%CI 37-43%）接受了 R0 切除术，中位总生存期为 15.5-35.4 个月，中位无进展生存期为 10.0-27.1 个月。荟萃分析表明，FOLFIRINOX 作为一线治疗，在 LAPC 或 BRPC 患者中具有显著的降期作用，R0 切除率为 40%，不良反应得到控制。
Zotero 插件